BNP Paribas Financial Markets Raises Stock Position in Liquidia Co. (NASDAQ:LQDA)

BNP Paribas Financial Markets grew its stake in Liquidia Co. (NASDAQ:LQDA - Free Report) by 735.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 140,190 shares of the company's stock after acquiring an additional 123,402 shares during the quarter. BNP Paribas Financial Markets owned about 0.18% of Liquidia worth $1,402,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the business. Price T Rowe Associates Inc. MD raised its position in shares of Liquidia by 26.4% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 14,341 shares of the company's stock valued at $212,000 after purchasing an additional 2,999 shares during the last quarter. California State Teachers Retirement System grew its holdings in shares of Liquidia by 491.2% during the first quarter. California State Teachers Retirement System now owns 46,181 shares of the company's stock valued at $681,000 after buying an additional 38,369 shares during the last quarter. DMC Group LLC acquired a new position in shares of Liquidia in the 2nd quarter valued at $122,000. Bank of New York Mellon Corp raised its stake in Liquidia by 18.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 207,961 shares of the company's stock worth $2,496,000 after acquiring an additional 32,076 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Liquidia by 398.1% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,039 shares of the company's stock worth $156,000 after acquiring an additional 10,421 shares during the period. 64.54% of the stock is owned by institutional investors and hedge funds.

Liquidia Stock Down 0.1 %

LQDA traded down $0.01 on Monday, reaching $11.00. The stock had a trading volume of 709,022 shares, compared to its average volume of 974,713. The business's 50-day moving average price is $10.84 and its two-hundred day moving average price is $11.29. Liquidia Co. has a 12-month low of $6.86 and a 12-month high of $16.99.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. Lifesci Capital assumed coverage on Liquidia in a report on Thursday, October 3rd. They issued an "outperform" rating and a $30.00 price objective on the stock. HC Wainwright reissued a "buy" rating and set a $29.00 price target on shares of Liquidia in a research report on Thursday, November 14th. BTIG Research decreased their price objective on shares of Liquidia from $29.00 to $25.00 and set a "buy" rating for the company in a research note on Monday, August 19th. Scotiabank assumed coverage on shares of Liquidia in a research note on Wednesday, October 16th. They issued a "sector outperform" rating and a $30.00 price objective on the stock. Finally, Raymond James upgraded shares of Liquidia from an "outperform" rating to a "strong-buy" rating in a research report on Monday, August 19th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Liquidia currently has an average rating of "Moderate Buy" and an average price target of $24.00.

Insiders Place Their Bets

In related news, CFO Michael Kaseta sold 3,892 shares of the company's stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $11.11, for a total transaction of $43,240.12. Following the completion of the transaction, the chief financial officer now owns 311,076 shares in the company, valued at $3,456,054.36. This represents a 1.24 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Rajeev Saggar sold 2,526 shares of the firm's stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $11.19, for a total transaction of $28,265.94. Following the completion of the transaction, the insider now directly owns 204,857 shares in the company, valued at $2,292,349.83. This represents a 1.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 22,007 shares of company stock worth $245,780. 30.10% of the stock is owned by corporate insiders.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).